Company Encyclopedia
View More
name
Polynovo Limited
PNV.AU
Medical device company, specializing in bioengineering technology
News
View More

UBS Group AG Ceases Substantial Holding in Polynovo

UBS Group AG has ceased to be a substantial shareholder in Polynovo Limited as of August 29, 2025. This change may affect Polynovo's shareholder composition and market perceptions, though specific implications were not detailed. The current analyst rating for Polynovo (AU:PNV) is a Hold with a price target of A$1.30. Polynovo's market cap stands at A$908.5M, with an average trading volume of 2,446,005 shares.

Tip Ranks·
Tip Ranks·

JPMorgan Increases Stake in Polynovo Limited

JPMorgan Chase & Co. has increased its stake in Polynovo Limited (AU:PNV), raising its voting power from 7.53% to 9.06% as of April 14, 2025. This change reflects a notable shift in shareholder interest, potentially impacting company decisions. Polynovo Limited, operating in the medical device sector, has experienced a year-to-date price performance decline of 33.17%, with a current market cap of $484.7 million.

Tip Ranks·
US
JPM
-0.14%
Tip Ranks·
US
JPM
-0.14%

JPMorgan Chase Increases Stake in Polynovo Limited

JPMorgan Chase & Co. has increased its stake in Polynovo Limited (AU:PNV), raising its voting power from 6.30% to 7.53%. This change indicates a significant shift in the company's shareholder structure, which may affect its market positioning and stakeholder relations. Polynovo's year-to-date price performance is down 40.96%, with an average trading volume of 4,474 and a current market cap of $415.9 million. For more details, visit TipRanks’ Stock Analysis page.

Tip Ranks·
US
JPM
-0.14%
Tip Ranks·
US
JPM
-0.14%

Polynovo Director’s Shareholding Adjusted by Personal Gift

Polynovo Limited (AU:PNV) announced a change in director David Williams' shareholding due to a personal gift. His spouse's entity, Lawn Views Pty Ltd, gifted 750 shares, reducing their total holdings to 21,420,635 shares. This off-market transaction has no direct impact on Polynovo's operations or market position. Polynovo focuses on developing innovative medical devices, particularly biodegradable polymers for treating burns and wounds, with a current market cap of $882.9M and a year-to-date price performance of 12.50%.

Tip Ranks·
Tip Ranks·